FAQ


Contact Us | LogIn     
Search
1546-2080 Online :: 1546-203X Print
Nanoparticle-based Therapeutics in Humans: A Survey
Volume 5, Issue 2


Authors:
Raj Bawa, Bawa Biotechnology Consulting LLC

Abstract:
With patent expirations on the rise, pharmaceutical companies are searching for new competitive business strategies. This is where nanomedicine comes into play. There is enormous excitement regarding nanomedicine’s potential impact. Drug delivery via nanoparticles presents novel therapeutic opportunities for active agents (drugs or genes) that were previously unsuited to traditional oral or injectable drug formulations, allowing active agents to be delivered efficaciously while minimizing side effects and leading to better patient compliance. Specifically, nanoparticle-based therapeutics have enormous potential in addressing the failures of traditional drugs that could not be effectively formulated due to factors such as poor water solubility or a lack of target specificity. Although there are only a few nanoparticle-based therapeutics on the market that have been approved by the FDA, these formulations are already impacting medicine and promise to alter healthcare. The initial impact of nanoparticlebased therapeutics will likely only accelerate in the coming years. However, as these products move out of the laboratory and into the clinic, federal agencies like the FDA and the U.S. Patent and Trademark Office continue to struggle to encourage the development of these products while imposing some sort of order. To date, numerous nanoparticles including luminescent quantum dots, magnetic nanoparticles, gold nanoshells, dendrimers and block copolymer micelles have been studied for drug delivery. In this article, Dr. Raj Bawa provides a brief overview of different nanoparticle technologies with some comments on their commercialization potential. In particular, he highlights selected nanoparticle-based therapeutics that are undergoing clinical trials or have been approved for human use.

Full Text (PDF)
Home   :   Aims & Scope    :   Editorial Board    :   Subscriptions   :   Partnerships  :   Disclaimer  :   Contact Us
Nanotechnology Law & Business Copyright 2005